Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remsima in moderate to severe plaque psoriasis
NCT06591273Phase 2Active, not recruiting
- Sponsor
- Services Institute of Medical Sciences
- Start
- Nov 2023
- Primary completion
- Nov 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of infliximab in plaque psoriasis, sponsored by Services Institute of Medical Sciences. Primary endpoints: At least 50% reduction in Psoriasis Area and Severity Index at 14 weeks and At least 50% reduction in Dermatology Life Quality Index at 14 weeks. Started Nov 2023; status: active, not recruiting.
02
Drugs
infliximab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT06591273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06591273.